抗HIV治療ガイドライン（2023年3月発行）

VII治療失敗時の薬剤変更

文献

  1. Nettles RE, Kieffer TL, Kwon P, et al. Intermittent HIV-1 viremia (Blips) and drug resistance in patients receiving HAART. JAMA. 293: 817-29, 2005
  2. Sklar PA, Ward DJ, Baker RK, et al. Prevalence and clinical correlates of HIV viremia ('blips') in patients with previous suppression below the limits of quantification. AIDS. 16: 2035-41, 2002.
  3. Martinez V, Marcelin AG, Morini JP, et al. HIV-1 intermittent viraemia in patients treated by nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS. 19: 1065-9, 2005.
  4. Havlir DV, Bassett R, Levitan D, et al. Prevalence and predictive value of intermittent viremia with combination HIV therapy. JAMA. 286: 171-9, 2001.
  5. Karlsson AC, Younger SR, Martin JN, et al. Immunologic and virologic evolution during periods of intermittent and persistent low-level viremia. AIDS. 18: 981-9, 2004.
  6. Hermankova M, Ray SC, Ruff C, et al. HIV-1 drug resistance profiles in children and adults with viral load of <50 copies/ml receiving combination therapy. JAMA. 286: 196-20, 2001.
  7. Masquelier B, Pereira E, Peytavin G, et al. Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance. J Clin Virol. 33: 75-8, 2005.
  8. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (米国DHHS, Sep 21, 2022). https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines
  9. Bartlett JA, DeMasi R, Quinn J, et al. Overview of the effectiveness of triple combination therapy in antiretroviral-naïve HIV-1 infected adults. AIDS. 15:1369-77.2001.
  10. harles H, Eron J., Fiscus S., et al. Transmitted HIV Resistance among Patients with Acute and Recent HIV Infection in North Carolina: Report of 102 Cases. 12th CROI abstract #673, 2005.
  11. Wensing AM, van de Vijver DA, Angarano G. et al. Prevalence of drug-resistant HIV-1 variants in untreated individuals in Europe: implications for clinical management. J Infect Dis. 192: 958-66, 2005.
  12. 国内流⾏HIV 及びその薬剤耐性株の⻑期的動向把握に関する研究班, 薬剤耐性HIV インフォメーションセンター https://www.hiv-resistance.jp/research03.htm.
  13. 蜂谷敦子、佐藤かおり、豊嶋崇徳ら. 国内新規HIV/AIDS診断症例における薬剤耐性HIV-1の動向. 日本エイズ学会誌. 21:465, 2019.
  14. King MS, Bernstein BM, Walmsley SL, et al. Baseline HIV-1 RNA level and CD4 cell count predict time to loss of virologic response to nelfinavir, but not lopinavir/ritonavir, in antiretroviral therapy- naïve patients. J Infect Dis. 190: 280-4, 2004.
  15. HIV診療における外来チーム医療マニュアル改訂第3版（厚生労働行政推進調査事業費補助金（エイズ対策政策研究事業）「HIV感染症及びその合併症の課題を克服する研究」班：https://osaka-hiv.jp/pdf/team_medical_manual_3.pdf
  16. Tural C, Ruiz L, Holtzer C, et al. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 16: 209-18, 2002.
  17. Stanford HIV Drug Resistance Database, HIVdb version 9.0 https://hivdb.stanford.edu/
  18. R. Stryker, S. Brun, M. King, et al. Kaletra (ABT-378/ritonavir) in Antiretroviral- naïve HIV+ Patients: Follow-up Beyond Two Years and Viral Load Suppression Below 3 Copies/m. 5TH INTERNATIONAL CONGRESS ON DRUG THERAPY IN HIV INFECTION, 2000.
  19. HIV薬剤耐性検査ガイドラインver.10 （日本医療研究開発機構 エイズ対策実用化研究事業「国内流行HIV及びその薬剤耐性株の長期的動向把握に関する研究」班）：https://www.hiv-resistance.jp/resistance04.htm
  20. Aboud M, Kaplan R, Lombaard J, et al. Dolutegravir versus ritonavir-boosted lopinavir both with dual nucleoside reverse transcriptase inhibitor therapy in adults with HIV-1 infection in whom first-line therapy has failed (DAWNING): an open-label, non-inferiority, phase 3b trial. Lancet Infect Dis. 19:253-264, 2019.
  21. aton N, Musaazi J, Kityo C, et al. Efficacy and safety of dolutegravir or darunavir in combination with lamivudine plus either zidovudine or tenofovir for second-line treatment of HIV infection (NADIA): week 96 results from a prospective, multicentre, open-label, factorial, randomised, non-inferiority trial. Lancet HIV. 9:e381-e393, 2022.

PAGE TOP